Xtl Biopharmaceuticals (XTLB) Cost of Revenue (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Cost of Revenue of $332000.0 for Q4 2024, up 174.38% on a QoQ basis from $121000.0 in Q3 2014.

Xtl Biopharmaceuticals (XTLB) Cost of Revenue (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Cost of Revenue for 5 consecutive years, with $332000.0 the latest figure, recorded in Q4 2024.

Quarterly Cost of Revenue changed N/A year-over-year to $332000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $723000.0 (changed N/A YoY) and the FY2025 annual result came in at $448000.0, changed 0.0% from the prior year.
Cost of Revenue grew to $332000.0 in Q4 2024 per XTLB's latest filing, from $121000.0 in the prior quarter.
Over the last five years, Cost of Revenue for XTLB reached as high as $332000.0 in Q4 2024 and fell as low as $332000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	167.22 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	392.80 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	296.00 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	145.00 Mn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Xtl Biopharmaceuticals	2.58 Bn	2.58 Bn	-	-

Download Data